I

IDEAYA Biosciences

Precision oncology therapies guided by biomarkers

Director, CMC Process Chemistry

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USA

About the Job

Requirements

  • A Ph.D. in Chemistry with at least 10 years, or an M.Sc. with at least 14 years, of chemical process development experience in a pharmaceutical or biotechnology company, and demonstrated ability to lead cross-functional groups.
  • A track record of successfully delivering timely drug substance and CMC activities spanning preclinical, IND-enabling, and NDA material supplies and commercialization.
  • A strong understanding of quality systems, including standard operating procedures, manufacturing batch record review, batch release and disposition, Good Documentation Practices, current good manufacturing practice data traceability, deviations, and change management.
  • Established knowledge and application of current industry standards and regulatory authority guidance and expectations, including ICH, FDA, and EMA guidelines.
  • Experience managing global contract development and manufacturing organizations, including dedicated full-time equivalent teams and fee-for-service projects.
  • Ability to travel domestically and internationally to oversee drug substance development and manufacturing at contract development and manufacturing organizations.
  • Ability to act with integrity and comply with applicable laws, regulations, and company policies, including the company's Code of Conduct.
  • Ability to exercise good judgment and ethical behavior in business activities, prioritize patient and product safety, and report suspected violations of law or company policy through appropriate channels.
  • Ability to be fully vaccinated against COVID-19, subject to reasonable accommodations or applicable law.

Responsibilities

  • Lead process chemistry efforts to facilitate drug substance development by managing multiple contract development and manufacturing organizations across preclinical, Phase I–III, and commercial stages; support traditional small-molecule targets and potentially scale-up of small-molecule antibody-drug conjugate payloads and linkers.
  • Author and review technical development reports, batch records, campaign reports, change controls, corrective and preventive actions, deviations, and investigations.
  • Author and review technical sections of IND, IMPD, and NDA documents for global CMC regulatory submissions, and stay current on health authority guidance and expectations.
  • Represent drug substance and CMC functions on cross-functional project teams, manage multiple priorities, and solve problems quickly to ensure timely drug substance supply for pharmacokinetic/pharmacodynamic, efficacy, dose-range-finding, and pilot toxicology studies, IND-enabling activities, and clinical trials across a portfolio of programs.
  • Collaborate with cross-functional teams, including Medicinal Chemistry, DMPK, Analytical Chemistry, Formulation, Toxicology, Quality, Project Management, CMC Regulatory, Development Sciences, and Clinical Pharmacology, to achieve project goals.
  • Communicate proactively and work with other functions to align drug substance and CMC strategies, maintain aggressive timelines, and achieve goals.
  • Lead the evaluation, selection, and management of contract development and manufacturing organizations for drug substance development and good manufacturing practice production.
  • Oversee technology transfer activities at contract development and manufacturing organizations to ensure successful manufacturing, and provide technical expertise to troubleshoot and resolve issues.

Desired Qualifications

  • Late-phase and commercial experience.
  • Experience manufacturing small-molecule antibody-drug conjugate payloads and linkers.

About the Company

IDEAYA Biosciences

Precision oncology therapies guided by biomarkers

IDEAYA Biosciences develops targeted cancer therapies by combining translational biomarkers with small molecule drug discovery to identify and treat specific patient populations defined by molecular diagnostics. Its product work relies on identifying biomarkers that predict which patients will respond to a given therapy and then designing and optimizing small molecules that target those biology. The company differentiates itself by grounding drug discovery in biomarker-driven precision medicine—mapping patient subgroups to therapies rather than pursuing broad oncology indications—and by pursuing partnerships and licensing to fund R&D and reach commercialization. The goal is to deliver precise, biomarker-guided cancer treatments that improve outcomes for defined patient groups and bring those therapies to market through collaborations and eventual sales of approved drugs.

Company size
201-500
Company stage
IPO
Headquarters
South San Francisco, CA
Founded
2015

Recently Posted Jobs

Explore more opportunities at IDEAYA Biosciences

See more jobs